NVO
Novo Nordisk A/S
NYSE · Healthcare · Drug Manufacturers - General · DK
$46.62
−1.87%Year over year
Reported trailing growth
- Revenue
- +5.6%
- EBITDA
- +4.7%
- EBIT
- -0.5%
- EPS
- +5.0%
- Free cash flow
- -21.1%
- Operating cash flow
- +9.4%
Forward estimates
Based on analyst estimates
- Revenue
- -10.7%
- EBITDA
- -11.2%
- EPS
- -23.0%
Three-year CAGR
- Revenue
- +20.4%
- EBITDA
- +26.8%
- EBIT
- +19.5%
- Net income
- +22.6%
- EPS
- +23.4%
- Free cash flow
- -23.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026